Molecular pharmacology in a simple model system: Implicating MAP kinase and phosphoinositide signalling in bipolar disorder

Seminars in Cell and Developmental Biology

Volumn 22, Issue 1, 2011, Pages 105-113

  Ludtmann, Marthe H R ^a   Boeckeler, Katrina ^a   Williams, Robin S B ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Bipolar disorder; Dictyostelium; Lithium; MAP kinase; Pharmacology; Phosphoinositol; Valproic acid

Indexed keywords

LITHIUM; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITIDE; VALPROIC ACID;

BIPOLAR DISORDER; DICTYOSTELIUM; DRUG MECHANISM; DRUG TARGETING; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TRANSLATION INITIATION;

ANIMALIA; DICTYOSTELIUM; RODENTIA;

EID: 78751701882     PISSN: 10849521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcdb.2010.11.002     Document Type: Review

References (109)

1. Jamison K.R. Manic-depressive illness and creativity. Sci Am 1995, 272(2):62-67.
2. Angst J., Gamma A., Benazzi F., Ajdacic V., Eich D., Rossler W. Diagnostic issues in bipolar disorder. Eur Neuropsychopharmacol 2003, 13(Suppl. 2):S43-S50.
3. Benazzi F. Frequency of bipolar spectrum in 111 private practice depression outpatients. Eur Arch Psychiatry Clin Neurosci 2003, 253(4):203-208.
4. Calabrese J.R., Hirschfeld R.M., Reed M., Davies M.A., Frye M.A., Keck P.E., et al. Impact of bipolar disorder on a US community sample. J Clin Psychiatry 2003, 64(4):425-432.
5. Evans D.L., Charney D.S. Mood disorders and medical illness: a major public health problem. Biol Psychiatry 2003, 54(3):177-180.
6. Ketter T.A. Diagnostic features, prevalence, and impact of bipolar disorder. J Clin Psychiatry 2010, 71(6):e14.
7. Tsuchiya K.J., Agerbo E., Byrne M., Mortensen P.B. Higher socio-economic status of parents may increase risk for bipolar disorder in the offspring. Psychol Med 2004, 34(5):787-793.
8. Fajutrao L., Locklear J., Priaulx J., Heyes A. A systematic review of the evidence of the burden of bipolar disorder in Europe. Clin Pract Epidemiol Ment Health 2009, 5:3.
9. McIntyre R.S., Muzina D.J., Kemp D.E., Blank D., Woldeyohannes H.O., Lofchy J., et al. Bipolar disorder and suicide: research synthesis and clinical translation. Curr Psychiatry Rep 2008, 10(1):66-72.
10. Moreno C., Laje G., Blanco C., Jiang H., Schmidt A.B., Olfson M. National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Arch Gen Psychiatry 2007, 64(9):1032-1039.
11. Craddock N., Forty L. Genetics of affective (mood) disorders. Eur J Hum Genet 2006, 14(6):660-668.
12. Gould T.D., Dow E.R., O'Donnell K.C., Chen G., Manji H.K. Targeting signal transduction pathways in the treatment of mood disorders: recent insights into the relevance of the Wnt pathway. CNS Neurol Disord Drug Targets 2007, 6(3):193-204.
13. Flaisher-Grinberg S., Kronfeld-Schor N., Einat H. Models of mania: from facets to domains and from animal models to model animals. J Psychopharmacol 2010, 24(3):437-438.
14. Craddock N., Sklar P. Genetics of bipolar disorder: successful start to a long journey. Trends Genet 2009, 25(2):99-105.
15. Baum A.E., Akula N., Cabanero M., Cardona I., Corona W., Klemens B., et al. A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry 2008, 13(2):197-207.
16. Craddock N., Jones L., Jones I.R., Kirov G., Green E.K., Grozeva D., et al. Strong genetic evidence for a selective influence of GABA(A) receptors on a component of the bipolar disorder phenotype. Mol Psychiatry 2010, 15(11):1121.
17. van der Schot A.C., Vonk R., Brans R.G., van Haren N.E., Koolschijn P.C., Nuboer V., et al. Influence of genes and environment on brain volumes in twin pairs concordant and discordant for bipolar disorder. Arch Gen Psychiatry 2009, 66(2):142-151.
18. Moore G.J., Cortese B.M., Glitz D.A., Zajac-Benitez C., Quiroz J.A., Uhde T.W., et al. A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients. J Clin Psychiatry 2009, 70(5):699-705.
19. Emsell L., McDonald C. The structural neuroimaging of bipolar disorder. Int Rev Psychiatry 2009, 21(4):297-313.
20. Nakatani N., Hattori E., Ohnishi T., Dean B., Iwayama Y., Matsumoto I., et al. Genome-wide expression analysis detects eight genes with robust alterations specific to bipolar I disorder: relevance to neuronal network perturbation. Hum Mol Genet 2006, 15(12):1949-1962.
21. Breen G., Harwood A.J., Gregory K., Sinclair M., Collier D., St C.D., et al. Two peptidase activities decrease in treated bipolar disorder not schizophrenic patients. Bipolar Disord 2004, 6(2):156-161.
22. Bazinet R.P., Rao J.S., Chang L., Rapoport S.I., Lee H.J. Chronic carbamazepine decreases the incorporation rate and turnover of arachidonic acid but not docosahexaenoic acid in brain phospholipids of the unanesthetized rat: relevance to bipolar disorder. Biol Psychiatry 2006, 59(5):401-407.
23. Lee H.J., Rao J.S., Chang L., Rapoport S.I., Kim H.W. Chronic imipramine but not bupropion increases arachidonic acid signaling in rat brain: is this related to 'switching' in bipolar disorder? Mol Psychiatry 2010, 15(6):602-614.
24. Kay R.R. Differentiation and patterning in Dictyostelium. Curr Opin Genet Dev 1994, 4(5):637-641.
25. Urushihara H. Developmental biology of the social amoeba: history, current knowledge and prospects. Dev Growth Differ 2008, 50(Suppl. 1):S277-S281.
26. Kimmel A.R., Firtel R.A. Breaking symmetries: regulation of Dictyostelium development through chemoattractant and morphogen signal-response. Curr Opin Genet Dev 2004, 14(5):540-549.
27. Surcel A., Kee Y.S., Luo T., Robinson D.N. Cytokinesis through biochemical-mechanical feedback loops. Semin Cell Dev Biol 2010, 10.
28. Buttery N.J., Rozen D.E., Wolf J.B., Thompson C.R. Quantification of social behavior in D. discoideum reveals complex fixed and facultative strategies. Curr Biol 2009, 19(16):1373-1377.
29. Eichinger L., Pachebat J.A., Glockner G., Rajandream M.A., Sucgang R., Berriman M., et al. The genome of the social amoeba Dictyostelium discoideum. Nature 2005, 435(7038):43-57.
30. Fey P., Gaudet P., Curk T., Zupan B., Just E.M., Basu S., et al. DictyBase-a Dictyostelium bioinformatics resource update. Nucleic Acids Res 2009, 37:D515-D519. (Database issue).
31. Kuspa A. Restriction enzyme-mediated integration (REMI) mutagenesis. Methods Mol Biol 2006, 346:201-209.
32. Kuspa A., Loomis W.F. REMI-RFLP mapping in the Dictyostelium genome. Genetics 1994, 138(3):665-674.
33. Kuspa A., Loomis W.F. Tagging developmental genes in Dictyostelium by restriction enzyme-mediated integration of plasmid DNA. Proc Natl Acad Sci USA 1992, 89(18):8803-8807.
34. Williams R.S. Pharmacogenetics in model systems: defining a common mechanism of action for mood stabilisers. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29(6):1029-1037.
35. Faix J., Kreppel L., Shaulsky G., Schleicher M., Kimmel A.R. A rapid and efficient method to generate multiple gene disruptions in Dictyostelium discoideum using a single selectable marker and the Cre-loxP system. Nucleic Acids Res 2004, 32(19):e143.
36. Hoeller O., Kay R.R. Chemotaxis in the absence of PIP3 gradients. Curr Biol 2007, 17(9):813-817.
37. Fischer M., Haase I., Wiesner S., Muller-Taubenberger A. Visualizing cytoskeleton dynamics in mammalian cells using a humanized variant of monomeric red fluorescent protein. FEBS Lett 2006, 580(10):2495-2502.
38. Meunier CARRAZ.G., Neunier Y., Eymard P., Aimard M. Pharmacodynamic properties of N-dipropylacetic acid. Therapie 1963, 18:435-438.
39. Gyulai L., Bowden C.L., McElroy S.L., Calabrese J.R., Petty F., Swann A.C., et al. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 2003, 28(7):1374-1382.
40. Keck P.E., McElroy S.L. Divalproex in the treatment of bipolar disorder. Psychopharmacol Bull 2003, 37(Suppl. 2):67-73.
41. Calabresi P., Galletti F., Rossi C., Sarchielli P., Cupini L.M. Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms. Trends Pharmacol Sci 2007, 28(4):188-195.
42. Costa C., Martella G., Picconi B., Prosperetti C., Pisani A., Di F.M., et al. Multiple mechanisms underlying the neuroprotective effects of antiepileptic drugs against in vitro ischemia. Stroke 2006, 37(5):1319-1326.
43. Blaheta R.A., Michaelis M., Driever P.H., Cinatl J. Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev 2005, 25(4):383-397.
44. Qing H., He G., Ly P.T., Fox C.J., Staufenbiel M., Cai F., et al. Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. J Exp Med 2008, 205(12):2781-2789.
45. Lehrman G., Hogue I.B., Palmer S., Jennings C., Spina C.A., Wiegand A., et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005, 366(9485):549-555.
46. Alam H.B., Shuja F., Butt M.U., Duggan M., Li Y., Zacharias N., et al. Surviving blood loss without blood transfusion in a swine poly-trauma model. Surgery 2009, 146(2):325-333.
47. Dash P.K., Orsi S.A., Zhang M., Grill R.J., Pati S., Zhao J., et al. Valproate administered after traumatic brain injury provides neuroprotection and improves cognitive function in rats. PLoS One 2010, 5(6):e11383.
48. Brown N.A., Farmer P.B., Coakley M. Valproic acid teratogenicity: demonstration that the biochemical mechanism differs from that of valproate hepatotoxicity. Biochem Soc Trans 1985, 13(1):75-77.
49. Lisi A., Botto L.D., Robert-Gnansia E., Castilla E.E., Bakker M.K., Bianca S., et al. Surveillance of adverse fetal effects of medications (SAFE-Med): findings from the international Clearinghouse of birth defects surveillance and research. Reprod Toxicol 2010, 29(4):433-442.
50. Powell-Jackson P.R., Tredger J.M., Williams R. Hepatotoxicity to sodium valproate: a review. Gut 1984, 25(6):673-681.
51. Terbach N., Williams R.S. Structure-function studies for the panacea, valproic acid. Biochem Soc Trans 2009, 37(Pt 5):1126-1132.
52. Agam G., Shamir A., Shaltiel G., Greenberg M.L. Myo-inositol-1-phosphate (MIP) synthase: a possible new target for antibipolar drugs. Bipolar Disord 2002, 4(Suppl. 1):15-20.
53. Shaltiel G., Mark S., Kofman O., Belmaker R.H., Agam G. Effect of valproate derivatives on human brain myo-inositol-1-phosphate (MIP) synthase activity and amphetamine-induced rearing. Pharmacol Rep 2007, 59(4):402-407.
54. Berridge M.J., Downes C.P., Hanley M.R. Neural and developmental actions of lithium: a unifying hypothesis. Cell 1989, 59(3):411-419.
55. Cunningham M.O., Woodhall G.L., Jones R.S. Valproate modifies spontaneous excitation and inhibition at cortical synapses in vitro. Neuropharmacology 2003, 45(7):907-917.
56. Bazinet R.P., Weis M.T., Rapoport S.I., Rosenberger T.A. Valproic acid selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by brain microsomal long-chain fatty acyl-CoA synthetases: relevance to bipolar disorder. Psychopharmacology (Berl) 2006, 184(1):122-129.
57. Hao Y., Creson T., Zhang L., Li P., Du F., Yuan P., et al. Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J Neurosci 2004, 24(29):6590-6599.
58. Chen G., Huang L.D., Jiang Y.M., Manji H.K. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 1999, 72(3):1327-1330.
59. Eickholt B.J., Towers G.J., Ryves W.J., Eikel D., Adley K., Ylinen L.M., et al. Effects of valproic acid derivatives on inositol trisphosphate depletion, teratogenicity, glycogen synthase kinase-3beta inhibition, and viral replication: a screening approach for new bipolar disorder drugs derived from the valproic acid core structure. Mol Pharmacol 2005, 67(5):1426-1433.
60. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001, 276(39):36734-36741.
61. DeSarno P., Li X., Jope R.S. Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 2002, 43(7):1158-1164.
62. Eikel D., Lampen A., Nau H. Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives. Chem Res Toxicol 2006, 19(2):272-278.
63. Cade J.F. Lithium salts in the treatment of psychotic excitement. Med J Aust 1949, 2(10):349-352.
64. Phiel C.J., Wilson C.A., Lee V.M., Klein P.S. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 2003, 423(6938):435-439.
65. Williams RS, Harwood AJ. Lithium metallotherapeutics. Metallotherapeutic drugs and metal-based diagnostic agents: the use of metals in medicine. Wiley; 2005.
66. Gagliardi J.P., Krishnan K.R. Evidence-based mental health use of anticonvulsants during pregnancy. Psychopharmacol Bull 2003, 37(2):59-66.
67. Doble B.W., Woodgett J.R. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003, 116(Pt 7):1175-1186.
68. Jope R.S., Roh M.S. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets 2006, 7(11):1421-1434.
69. Einat H., Manji H.K. Cellular plasticity cascades: genes-to-behavior pathways in animal models of bipolar disorder. Biol Psychiatry 2006, 59(12):1160-1171.
70. King J.S., Teo R., Ryves J., Reddy J.V., Peters O., Orabi B., et al. The mood stabiliser lithium suppresses PIP3 signalling in Dictyostelium and human cells. Dis Model Mech 2009, 2(5-6):306-312.
71. Bachmann R.F., Schloesser R.J., Gould T.D., Manji H.K. Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics. Mol Neurobiol 2005, 32(2):173-202.
72. Manji H.K., Duman R.S. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol Bull 2001, 35(2):5-49.
73. Drevets W.C. Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol 2001, 11(2):240-249.
74. Strakowski S.M., Adler C.M., Holland S.K., Mills N.P., Delbello M.P., Eliassen J.C. Abnormal FMRI brain activation in euthymic bipolar disorder patients during a counting Stroop interference task. Am J Psychiatry 2005, 162(9):1697-1705.
75. Rajkowska G., Halaris A., Selemon L.D. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol Psychiatry 2001, 49(9):741-752.
76. Chen G., Zeng W.Z., Yuan P.X., Huang L.D., Jiang Y.M., Zhao Z.H., et al. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 1999, 72(2):879-882.
77. Fukumoto T., Morinobu S., Okamoto Y., Kagaya A., Yamawaki S. Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology (Berl) 2001, 158(1):100-106.
78. Einat H., Manji H.K., Gould T.D., Du J., Chen G. Possible involvement of the ERK signaling cascade in bipolar disorder: behavioral leads from the study of mutant mice. Drug News Perspect 2003, 16(7):453-463.
79. Einat H., Yuan P., Gould T.D., Li J., Du J., Zhang L., et al. The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci 2003, 23(19):7311-7316.
80. Yuan P.X., Huang L.D., Jiang Y.M., Gutkind J.S., Manji H.K., Chen G. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem 2001, 276(34):31674-31683.
81. Mathew S.J., Manji H.K., Charney D.S. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology 2008, 33(9):2080-2092.
82. Boeckeler K., Adley K., Xu X., Jenkins A., Jin T., Williams R.S. The neuroprotective agent, valproic acid, regulates the mitogen-activated protein kinase pathway through modulation of protein kinase A signalling in Dictyostelium discoideum. Eur J Cell Biol 2006, 85(9-10):1047-1057.
83. Gerits N., Kostenko S., Shiryaev A., Johannessen M., Moens U. Relations between the mitogen-activated protein kinase and the cAMP-dependent protein kinase pathways: comradeship and hostility. Cell Signal 2008, 20(9):1592-1607.
84. Kassahun K., Abbott F. In vivo formation of the thiol conjugates of reactive metabolites of 4-ene VPA and its analog 4-pentenoic acid. Drug Metab Dispos 1993, 21(6):1098-1106.
85. Tasso S.M., Moon S.C., Bruno-Blanch L.E., Estiu G.L. Characterization of the anticonvulsant profile of valpromide derivatives. Bioorg Med Chem 2004, 12(14):3857-3869.
86. Gotfryd K., Owczarek S., Hoffmann K., Klementiev B., Nau H., Berezin V., et al. Multiple effects of pentyl-4-yn-VPA enantiomers: from toxicity to short-term memory enhancement. Neuropharmacology 2007, 52(3):764-778.
87. Dhikav V., Anand K.S. Is hippocampal atrophy a future drug target? Med Hypotheses 2007, 68(6):1300-1306.
88. Mann L., Heldman E., Shaltiel G., Belmaker R.H., Agam G. Lithium preferentially inhibits adenylyl cyclase V and VII isoforms. Int J Neuropsychopharmacol 2008, 11(4):533-539.
89. Mann L., Heldman E., Bersudsky Y., Vatner S.F., Ishikawa Y., Almog O., et al. Inhibition of specific adenylyl cyclase isoforms by lithium and carbamazepine, but not valproate, may be related to their antidepressant effect. Bipolar Disord 2009, 11(8):885-896.
90. Montezinho L.P., Castro M.M., Duarte C.B., Penschuck S., Geraldes C.F., Mork A. The interaction between dopamine D2-like and beta-adrenergic receptors in the prefrontal cortex is altered by mood-stabilizing agents. J Neurochem 2006, 96(5):1336-1348.
91. Montezinho L.P., Mork A., Duarte C.B., Penschuck S., Geraldes C.F., Castro M.M. Effects of mood stabilizers on the inhibition of adenylate cyclase via dopamine D(2)-like receptors. Bipolar Disord 2007, 9(3):290-297.
92. Gallagher H.C., Bacon C.L., Odumeru O.A., Gallagher K.F., Fitzpatrick T., Regan C.M. Valproate activates phosphodiesterase-mediated cAMP degradation: relevance to C6 glioma G1 phase progression. Neurotoxicol Teratol 2004, 26(1):73-81.
93. Williams R.S., Cheng L., Mudge A.W., Harwood A.J. A common mechanism of action for three mood-stabilizing drugs. Nature 2002, 417(6886):292-295.
94. Hallcher L.M., Sherman W.R. The effects of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. J Biol Chem 1980, 255(22):10896-10901.
95. Williams R.S., Eames M., Ryves W.J., Viggars J., Harwood A.J. Loss of a prolyl oligopeptidase confers resistance to lithium by elevation of inositol (1,4,5) trisphosphate. EMBO J 1999, 18(10):2734-2745.
96. Sarkar S., Floto R.A., Berger Z., Imarisio S., Cordenier A., Pasco M., et al. Lithium induces autophagy by inhibiting inositol monophosphatase. J Cell Biol 2005, 170(7):1101-1111.
97. Schulz I., Gerhartz B., Neubauer A., Holloschi A., Heiser U., Hafner M., et al. Modulation of inositol 1,4,5-triphosphate concentration by prolyl endopeptidase inhibition. Eur J Biochem 2002, 269(23):5813-5820.
98. Williams R.S.B. Prolyl oligopeptidase and bipolar disorder. Clinical Neuroscience Research 2004, 4(3-4):233-242.
99. Shimshoni J.A., Dalton E.C., Jenkins A., Eyal S., Ewan K., Williams R.S., et al. The effects of central nervous system-active valproic acid constitutional isomers, cyclopropyl analogs, and amide derivatives on neuronal growth cone behavior. Mol Pharmacol 2007, 71(3):884-892.
100. King J., Keim M., Teo R., Weening K.E., Kapur M., McQuillan K., et al. Genetic control of lithium sensitivity and regulation of inositol biosynthetic genes. PLoS One 2010, 5(6):e11151.
101. Sjoholt G., Ebstein R.P., Lie R.T., Berle J.O., Mallet J., Deleuze J.F., et al. Examination of IMPA1 and IMPA2 genes in manic-depressive patients: association between IMPA2 promoter polymorphisms and bipolar disorder. Mol Psychiatry 2004, 9(6):621-629.
102. Sjoholt G., Gulbrandsen A.K., Lovlie R., Berle J.O., Molven A., Steen V.M. A human myo-inositol monophosphatase gene (IMPA2) localized in a putative susceptibility region for bipolar disorder on chromosome 18p11.2: genomic structure and polymorphism screening in manic-depressive patients. Mol Psychiatry 2000, 5(2):172-180.
103. Ohnishi T., Yamada K., Ohba H., Iwayama Y., Toyota T., Hattori E., et al. A promoter haplotype of the inositol monophosphatase 2 gene (IMPA2) at 18p11.2 confers a possible risk for bipolar disorder by enhancing transcription. Neuropsychopharmacology 2007 Aug, 32(8):1727-1737.
104. Xu X., Muller-Taubenberger A., Adley K.E., Pawolleck N., Lee V.W., Wiedemann C., et al. Attenuation of phospholipid signaling provides a novel mechanism for the action of valproic acid. Eukaryot Cell 2007, 6(6):899-906.
105. Pawolleck N., Williams R.S. Quantifying in vivo phosphoinositide turnover in chemotactically competent Dictyostelium cells. Methods Mol Biol 2009, 571:283-290.
106. Brown A.S., Mallinger A.G., Renbaum L.C. Elevated platelet membrane phosphatidylinositol-4,5-bisphosphate in bipolar mania. Am J Psychiatry 1993, 150(8):1252-1254.
107. Soares J.C., Dippold C.S., Mallinger A.G. Platelet membrane phosphatidylinositol-4,5-bisphosphate alterations in bipolar disorder--evidence from a single case study. Psychiatry Res 1997, 69(2-3):197-202.
108. Soares J.C., Mallinger A.G., Dippold C.S., Forster W.K., Frank E., Kupfer D.J. Effects of lithium on platelet membrane phosphoinositides in bipolar disorder patients: a pilot study. Psychopharmacology (Berl) 2000, 149(1):12-16.
109. Pandey G.N., Ren X., Dwivedi Y., Pavuluri M.N. Decreased protein kinase C (PKC) in platelets of pediatric bipolar patients: effect of treatment with mood stabilizing drugs. J Psychiatr Res 2008, 42(2):106-116.